T Cell News and Research

Latest T Cell News and Research

Progenitor-cell therapy can reduce risk of another heart attack

Cells from heart attack survivors' own bone marrow reduced the risk of death or another heart attack when they were infused into the affected artery after successful stent placement, according to research reported in the American Heart Association journal Circulation: Heart Failure.

9 Dec 2009

Multi-institutional study identifies potential treatment target for ovarian cancer

A multi-institutional study has identified a potential personalized treatment target for the most common form of ovarian cancer. In the December 8 issue of Cancer Cell, the research team describes finding that a gene called MAGP2 - not previously associated with any type of cancer - was overexpressed in papillary serous ovarian tumors of patients who died more quickly. They also found evidence suggesting possible mechanisms by which MAGP2 may promote tumor growth.

9 Dec 2009

Xanthohumol compound may aid in preventing prostate cancer

The natural compound xanthohumol blocks the effects of the male hormone testosterone, therefore aiding in the prevention of prostate cancer.

9 Dec 2009

Immune-boosting drug: A new way for improving cancer treatment

Stimulating the body's own immune system to fight cancer offers new treatment opportunities for cancer patients, and scientists have made the first step towards finding existing drugs that could help.

9 Dec 2009

New breakthrough study shows reconstruction of human mandible bone with dental stem cells

In a statement today, StemSave(TM), Inc., the market leader in the field of stem cell recovery and cryo-preservation lauds research published in the November issue of the European Cells and Materials Journal citing the reconstruction of the human mandible bone with autologous dental pulp stem cells.

9 Dec 2009

Bird influenza viruses have a variety of strategies to cross the species barrier

The 2009 H1N1 influenza virus used a new strategy to cross from birds into humans, a warning that it has more than one trick up its sleeve to jump the species barrier and become virulent.

9 Dec 2009

Combination of gene and cell therapy improves critical limb ischemia associated with aging or diabetes

Blood vessel blockage, a common condition in old age or diabetes, leads to low blood flow and results in low oxygen, which can kill cells and tissues. Such blockages can require amputation resulting in loss of limbs. Now, using mice as their model, researchers at Johns Hopkins have developed therapies that increase blood flow, improve movement and decrease tissue death and the need for amputation.

8 Dec 2009

MCG receives $1.8M stimulus grant

It's a $1.8 million shot in the arm to the largest grant the Medical College of Georgia has ever received.

8 Dec 2009

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company’s oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.

8 Dec 2009

RIVA System effective in automatically compounding IV doses in syringes with minimal contamination

A recent study demonstrated the RIVA System (Robotic Intravenous Automation) - a self-contained unit for aseptic compounding from Intelligent Hospital Systems (IH Systems) - is an effective tool in automatically compounding IV doses in syringes and bags with minimal drug contamination.

8 Dec 2009

Micromet presents final data from its blinatumomab Phase 2 study for ALL

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL).

8 Dec 2009

Updated data from Allos Therapeutics' ongoing FOLOTYN study

Allos Therapeutics, Inc. today announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). These data were showcased during an oral presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA.

8 Dec 2009

CombinatoRx presents encouraging results from its A2A and b2AR agonist programs for B-cell malignancies

CombinatoRx, Incorporated today announced that preclinical data from its Adenosine A2A receptor (A2A) and Beta-2 Adrenergic Receptor (b2AR) Agonist oncology programs demonstrated synergistic anti-cancer activity when combined with standard-of-care therapies in multiple myeloma and other B-cell malignancies.

8 Dec 2009

Acceleron Pharma's ACE-536 stimulates red blood cell production through novel mechanism

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, presented data demonstrating that ACE-536 promotes formation of red blood cells through inhibition of members of the TGF-beta superfamily, at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Hemaquest Pharmaceuticals' HQK-1001 holds promise for sickle cell disease and beta thalassemia

HemaQuest Pharmaceuticals presented data from new preclinical studies and early results from clinical trials of its lead drug candidate, HQK-1001, in sickle cell disease and beta thalassemia at the annual meeting of the American Society of Hematology in New Orleans.

8 Dec 2009

Three university academic groups sponsored for the MetaMiner project

GeneGo, Inc., the leading systems biology tools company, announced today that Millipore Corporation has sponsored academic groups from University of Queensland, Sheffield and USC to become members of the collaborative MetaMiner (Stem Cells) project run by GeneGo. MetaMiner is a partnership program for the reconstruction of stem cell pathways and their application in analysis of experimental data as well as knowledge mining.

8 Dec 2009

Interim data from Geron's GRNVAC1 phase II trial for AML presented

Geron Corporation today announced the presentation of interim data from its phase II trial of GRNVAC1, an autologous dendritic cell vaccine targeting telomerase, in patients with acute myelogenous leukemia (AML) at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.

8 Dec 2009

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy.

8 Dec 2009

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Cell Therapeutics, Inc. announced today an abstract to be published online at the journal Blood website by M. Hacker, et al. demonstrating significant reduction in cardiac cell toxicity with pixantrone compared to currently marketed anthracyclines. The authors conclude that the reduction is due to pixantrone's inability to generate toxic drug iron complexes and reduced propensity to generate oxygen free radicals.

8 Dec 2009

$Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma$

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced results from an ongoing Phase 2 study, known as the 004 study, of the company's lead proteasome inhibitor, carfilzomib.

8 Dec 2009

T Cell News and Research

Latest T Cell News and Research

Progenitor-cell therapy can reduce risk of another heart attack

Multi-institutional study identifies potential treatment target for ovarian cancer

Xanthohumol compound may aid in preventing prostate cancer

Immune-boosting drug: A new way for improving cancer treatment

New breakthrough study shows reconstruction of human mandible bone with dental stem cells

Bird influenza viruses have a variety of strategies to cross the species barrier

Combination of gene and cell therapy improves critical limb ischemia associated with aging or diabetes

MCG receives $1.8M stimulus grant

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

RIVA System effective in automatically compounding IV doses in syringes with minimal contamination

Micromet presents final data from its blinatumomab Phase 2 study for ALL

Updated data from Allos Therapeutics' ongoing FOLOTYN study

CombinatoRx presents encouraging results from its A2A and b2AR agonist programs for B-cell malignancies

Acceleron Pharma's ACE-536 stimulates red blood cell production through novel mechanism

Hemaquest Pharmaceuticals' HQK-1001 holds promise for sickle cell disease and beta thalassemia

Three university academic groups sponsored for the MetaMiner project

Interim data from Geron's GRNVAC1 phase II trial for AML presented

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in